Endo Pharmaceuticals

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Endo Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).

23 total trials none currently recruiting 22 completed top decile by trial count

Endo Pharmaceuticals: 23 sponsored US clinical trials, none currently recruiting.

Endo Pharmaceuticals sponsors 23 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 22 completed. 12 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Edematous Fibrosclerotic Panniculopathy, with 4 trials.

Top-decile sponsor footprint

Endo Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

22 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

23 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

NCT06151197
COMPLETED Phase 2

Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

NCT05419505
COMPLETED Phase 3

Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis

NCT05254457
COMPLETED

Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)

NCT04381117
COMPLETED Phase 3

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

NCT03526549
COMPLETED Phase 2

Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

NCT02193828
COMPLETED Phase 2

Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder

NCT02006719
COMPLETED Phase 2

A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

NCT01987986
COMPLETED Phase 1

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT01774435
COMPLETED Phase 1

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT01518907
COMPLETED Phase 2

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

NCT01483963
COMPLETED

Retrospective Chart Review of Valstar

NCT01304173
COMPLETED Phase 3

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221623
COMPLETED Phase 3

Study of AA4500 in the Treatment of Peyronie's Disease

NCT01221597
COMPLETED Phase 3

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

NCT00528424
COMPLETED Phase 1

A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture

NCT00528931
COMPLETED Phase 3

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

NCT00226421
COMPLETED Phase 3

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

NCT00226395
COMPLETED Phase 4

Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

NCT00904475
COMPLETED Phase 4

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
COMPLETED Phase 4

Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

NCT00903851
COMPLETED Phase 4

Topical Lidocaine Patch in Low Back Pain

NCT00904540
COMPLETED Phase 2

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

NCT01316874

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6
Phase 3 8
Phase 4 4

Therapeutic Areas

Edematous Fibrosclerotic Panniculopathy 4
Cellulite 3
Peyronie's Disease 2
Plantar Fibromatosis 2
Frozen Shoulder 2
Adhesive Capsulitis 2
Advanced Dupuytren's Disease 1
Carcinoma in Situ of Bladder 1
Edematous Fibrosclerotic Panniculopathy (EFP) 1
Idiopathic Sensory Neuropathy 1

How the Endo Pharmaceuticals archive is shaped

23 indexed studies, none listed as recruiting (0% open); 22 completed (96%).

Phase mix: 12 late (III/IV) vs 9 early (I/II) (balanced across stages).

Top condition: Edematous Fibrosclerotic Panniculopathy (4 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Endo Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 23 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Endo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15%20%25% Total trials Recruiting share Endo PharmaceuticalsAMAG PharmaceuticalsAtriCureCara TherapeuticsCraig L Slingluff, Jr10xBio22nd Century Group23andMe3-C Institute for Social Development
Endo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Endo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 23 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Endo Pharmaceuticals page

23 registered trials is a research-attention snapshot, not an endorsement of Endo Pharmaceuticals or any single study.

  • None of Endo Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Edematous Fibrosclerotic Panniculopathy is the condition Endo Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Edematous Fibrosclerotic Panniculopathy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Endo Pharmaceuticals pipeline card: 23 registered trials from official public datasets.Report a data error.